Abstract
Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Current Pharmaceutical Design
Title:Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine
Volume: 20 Issue: 14
Author(s): Gilles Mees, Mike Sathekge, Alex Maes and Christophe Van de Wiele
Affiliation:
Keywords: Hypoxia, PET, SPECT, nitroimidazole.
Abstract: Hypoxia is a characteristic feature of many solid tumors which has been described in a wide range of tumor types. Its presence impairs the effectiveness of common anti-cancer therapies and accordingly, tumor hypoxia has been associated with an aggressive tumor phenotype, poor response to radio- and chemotherapy, and worse prognosis. In order to predict outcome and identify patients with a worse prognosis and/or patients that would benefit from appropriate treatments, in vivo measurement of tumor hypoxia is required. Given the difficulties associated with invasive methods, a non-invasive method is of major clinical interest. Although several candidate molecules have been labeled with PET and SPECT labels, none of them is used in daily clinical routine due to a number of difficulties that complicate their use. This review aims to give an overview of the most important hypoxia tracers, their prognostic significance and how these tracers can play a role in tomorrows personalized medicine.
Export Options
About this article
Cite this article as:
Mees Gilles, Sathekge Mike, Maes Alex and Wiele Van de Christophe, Radiolabelled Probes Targeting Tumor Hypoxia for Personalized Medicine, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113196660662
DOI https://dx.doi.org/10.2174/13816128113196660662 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Coronary Pressure Measurement Based Decision Making for Percutaneous Coronary Intervention
Current Cardiology Reviews Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery <i>In Vivo</i> Tracking of Novel SPIO-Molday ION Rhodamine-B™-Labeled Human Bone Marrow-Derived Mesenchymal Stem Cells After Lentivirus- Mediated COX-2 Silencing: A Preliminary Study
Current Gene Therapy Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Protecting Endothelium in Cardiovascular Diseases
Current Medicinal Chemistry Future of Cardiac Pacemaker – an Update of Biological Pacemaker Patents
Recent Patents on Biomedical Engineering (Discontinued) Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design Experimental Developments and Review of Recent Patents for the Repair of Skeletal Muscles by Methods of Regenerative Medicine
Recent Patents on Regenerative Medicine Cardioprotection Acquired Through Exercise: The Role of Ischemic Preconditioning
Current Cardiology Reviews The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Matrix Metalloproteinases and Vulnerable Atheromatous Plaque
Current Topics in Medicinal Chemistry Novel Findings and Therapeutic Targets on Cardioprotection of Ischemia/ Reperfusion Injury in STEMI
Current Pharmaceutical Design Cardiac Surgery and Inflammation: The Inflammatory Response and Strategies to Reduce the Systemic Inflammatory Response Syndrome
Current Cardiology Reviews Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued) The Role of Stem Cells in Muscular Dystrophies
Current Gene Therapy Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Computed Tomography Imaging of the Coronary Arteries: State of the Art Applications and Recent Patents
Recent Patents on Medical Imaging Radiofluorinated Carbohydrates for Positron Emission Tomography
Current Topics in Medicinal Chemistry